Immutep Limited: Continuing To Make The Case For Eftilagimod
Source: SeekingAlpha
2025-01-28 16:37:29 ET
Summary
- Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics.
- Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential.
- Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns.
- Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep Limited
NASDAQ: IMMP
IMMP Trading
-14.22% G/L:
$0.4556 Last:
5,373,194 Volume:
$0.49 Open:
IMMP Latest News
March 13, 2026 08:00:00 am
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
February 06, 2026 08:00:00 am
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
IMMP Stock Data
$413,609,616
143,291,445
N/A
6
N/A
Biotechnology & Life Sciences
Healthcare
AU
Sydney
